Topiramate for Weight Loss: Qsymia, Evidence, and Side Effects

How Phentermine-Topiramate Works

The two drugs act through different, complementary mechanisms. Phentermine is a stimulant that suppresses appetite by increasing norepinephrine signaling in the brain's hunger-regulating centers — the same mechanism it's used for alone, on a short-term basis, in its older single-ingredient form. Topiramate's exact weight-loss mechanism is less fully understood than phentermine's, but it's believed to increase satiety and reduce the rewarding, craving-driven aspect of eating, partly through effects on GABA and glutamate signaling. Combining the two at lower doses than either would use alone was designed to preserve efficacy while reducing the side-effect burden of either drug at a higher solo dose.

What the Clinical Trials Found

Qsymia's FDA approval was based on large phase 3 trials — including the EQUIP and CONQUER trials — that ran for a year in adults with obesity or overweight with a weight-related condition. Averaged across dose levels, participants lost meaningfully more weight than those on placebo, with the top approved dose producing the largest average loss. That places Qsymia's efficacy above older weight-loss drugs and below the newer GLP-1/GIP-based drugs (semaglutide and tirzepatide), which produce substantially larger average weight loss in their own head-to-head trials. See our Ozempic weight loss guide for what those trials showed by comparison.

Side Effects and Who Should Be Cautious

Because Qsymia combines a stimulant and an anticonvulsant, its side-effect profile is different in kind from the GI-dominant pattern seen with GLP-1 drugs:

• Paresthesia — tingling or numbness in the hands, feet, or face is one of the most commonly reported side effects, tied to topiramate's carbonic-anhydrase-inhibiting effect.
• Cognitive effects — difficulty concentrating, word-finding trouble, and memory issues are recognized topiramate side effects, sometimes significant enough that people discontinue the medication.
• Mood changes — topiramate carries its own labeling around mood and behavioral changes, and anyone with a history of depression or anxiety should discuss this specifically with their prescriber.
• Increased heart rate — a known effect of the phentermine component; people with uncontrolled hypertension or cardiovascular disease are generally not candidates.
• Kidney stones and metabolic acidosis — topiramate increases kidney stone risk and can lower blood bicarbonate; adequate hydration and periodic monitoring are part of standard care.

The Pregnancy Warning

Qsymia carries an FDA boxed warning — its most serious label warning category — because topiramate is associated with an increased risk of oral clefts (cleft lip and/or cleft palate) in infants exposed during the first trimester. Because of this, Qsymia is contraindicated in pregnancy, and prescribers require a negative pregnancy test before starting and reliable contraception while taking it for anyone who could become pregnant. This is a materially different risk profile from the GLP-1 drugs, which are also avoided in pregnancy but for different, less severe documented reasons (primarily lack of safety data rather than a specific established birth-defect signal).

Qsymia vs GLP-1 Drugs at a Glance

Qsymia and the GLP-1/GIP drug class solve the same problem through completely different mechanisms, which shows up clearly once the numbers are lined up side by side.

Verdict: pick Qsymia when access, cost, or a strong preference for an oral pill rules out GLP-1 drugs; pick a GLP-1 drug when maximum average weight loss is the priority and coverage allows it. Qsymia's roughly 9-10% average trial result is real and clinically meaningful — it simply sits well below what the newer incretin-based drugs post in their own trials. See our Ozempic vs Mounjaro and Wegovy vs Zepbound comparisons for how the GLP-1-class options stack up against each other.

Who Qsymia Is a Reasonable Option For

Qsymia is generally discussed as an option for people who prefer an oral pill over an injection, cannot tolerate or access GLP-1 drugs, or whose insurance covers it more readily than a GLP-1 medication. It is not typically the first choice when GLP-1 access isn't a barrier, given the meaningfully larger average weight loss seen with semaglutide and tirzepatide in trials. It is not an option at all for anyone who is pregnant, trying to conceive without reliable contraception, or has uncontrolled cardiovascular disease. As with any weight-loss medication, the decision belongs with a prescriber who can weigh your specific health history against the alternatives — see our metformin alternatives comparison for how the full range of options, prescription and non-prescription, stack up.